BioBrief covers the highest-signal biopharma developments from Monday, April 27th. Today’s episode focuses on Intellia’s Phase 3 in vivo CRISPR data, Sun Pharma’s $11.75 billion Organon acquisition, Oruka’s Phase 2a psoriasis readout, and Jazz’s FDA Priority Review catalyst in HER2-positive gastroesophageal cancer.

1. Intellia / lonvo-z
   • Mechanism: one-time in vivo CRISPR edit of KLKB1 to reduce kallikrein activity
   • Indication: hereditary angioedema
   • Stage: Phase 3; rolling BLA started
   • Key result: 87% attack reduction versus placebo; 62% attack-free and therapy-free versus 11% on placebo
   • Why it matters: randomized Phase 3 data materially improve approval probability for a one-time gene-editing therapy, though commercial uptake must compete with effective chronic drugs.
 ...